Stocktoria
Shattuck Labs, Inc. STTK
Shattuck Labs, Inc. (STTK) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.0M at a -4880.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.829 |
| Retained earnings / assets | -4.73 |
| EBIT / assets | -0.566 |
| Equity / liabilities | 9.54 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| STTK | Shattuck Labs, Inc. | 3/9 | -3.77 | — | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | 3/9 | — | — | — |
| DARE | Dare Bioscience, Inc. | 3/9 | — | — | — |
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| RLYB | Rallybio Corp | 3/9 | 0.76 | — | — |
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
FAQ
Is STTK financially healthy?
Shattuck Labs, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does STTK pay a dividend?
No, Shattuck Labs, Inc. does not currently pay a dividend.
How profitable is STTK?
In FY2025, Shattuck Labs, Inc. had a net margin of -4880.9% and a return on equity of -59.2%.
What is the analyst price target for STTK?
The average Wall-Street price target for Shattuck Labs, Inc. is $14.83, about 98.0% above the recent price, from 6 analysts (consensus: strong buy).
Is STTK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Shattuck Labs, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.